European regulator launches review of German vaccine CureVac

Vaccination: European regulator launches review of German vaccine CureVac – AFP

The European Medicines Agency (EMA) announced on Friday that it was starting a “continuous review” of the German CureVac vaccine against Covid-19, the first step towards a formal marketing authorization request in the European Union.

The decision “is based on preliminary results from laboratory studies (non-clinical data) and early clinical studies in adults,” the Amsterdam-based agency said in a statement.

Pressure to authorize new vaccines

“The continuous review will continue until sufficient evidence is available for an official application for marketing authorization,” added the European regulator, adding that it will assess data from other clinical trials ” as soon as they are available ”.

The EMA faces increased pressure to clear new anti-Covid vaccines as quickly as possible, as the 27 member states grapple with delivery delays and supply difficulties for the first three vaccines authorized in the ‘European Union.

Bayer commits to producing CureVac

Developed by the German biotech company of the same name, the CureVac messenger RNA vaccine, which pharmacy giant Bayer has committed to producing, is currently in phase 3 clinical trials.

Peter Kremsner, professor at the Institute of Tropical Medicine in Tübingen, who is overseeing the ongoing clinical study, told German television on Friday that “the authorization (from the EMA) could come in April if all goes good “. The agency for its part underlined “not being able to predict a general timetable”, although the evaluation of a possible request is facilitated by the process of “continuous examination”.

This procedure allows the EMA to examine vaccine safety and efficacy data as they become available, even before a formal request for authorization is submitted by the manufacturer. Its purpose is to speed up the assessment of a marketing authorization application once it has been formulated.

“Continuous review” for two other vaccines

Two other vaccines are currently the subject of a “continuous review”, namely that developed by the American company Johnson & Johnson and that of the American group Novavax.

The EMA has so far given the green light for conditional marketing in the EU for three vaccines: those from Pfizer / BioNTech, Moderna and AstraZeneca / Oxford.

Source: 20Minutes – Une by

*The article has been translated based on the content of 20Minutes – Une by If there is any problem regarding the content, copyright, please leave a report below the article. We will try to process as quickly as possible to protect the rights of the author. Thank you very much!

*We just want readers to access information more quickly and easily with other multilingual content, instead of information only available in a certain language.

*We always respect the copyright of the content of the author and always include the original link of the source article.If the author disagrees, just leave the report below the article, the article will be edited or deleted at the request of the author. Thanks very much! Best regards!